Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.

Autor: Cheung GC; Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore., Yoon YH; Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Chen LJ; MacKay Memorial Hospital, Taipei, Taiwan., Chen SJ; Department of Ophthalmology, Taipei Veterans General Hospital, School of Medicine, National Yang Ming University, Taipei, Taiwan., George TM; Sunway Medical Centre, Eye Centre, Petaling Jaya, Malaysia., Lai TY; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong., Park KH; Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea., Tahija SG; Klinik Mata Nusantara, Jakarta, Indonesia., Uy HS; Department of Ophthalmology and Visual Sciences, University of the Philippines, Philippine General Hospital, Manila, Philippines., Wong TY; Singapore National Eye Centre, Singapore.
Jazyk: angličtina
Zdroj: Clinical & experimental ophthalmology [Clin Exp Ophthalmol] 2018 Jan; Vol. 46 (1), pp. 75-86. Date of Electronic Publication: 2017 Jun 21.
DOI: 10.1111/ceo.12999
Abstrakt: Diabetic macular oedema is the most common cause of diabetic retinopathy-induced vision loss. Efficacy of anti-vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. An Asian-specific guideline for diabetic macular oedema treatment is needed as patients in Asia tend to present with far more advanced disease than seen elsewhere in the world. Previous reviews of diabetic macular oedema management lacked a broader assessment of anti-vascular endothelial growth factor treatment choices and newer trials. Recent clinical trial data allow head-to-head comparisons between the different anti-vascular endothelial growth factor agents and treatment regimens. This review aims to summarize the clinical evidence related to various treatment regimens for clinicians, with a focus on anti-vascular endothelial growth factor therapies, and to provide guidance on the treatment of diabetic macular oedema in Asian patients.
(© 2017 Royal Australian and New Zealand College of Ophthalmologists.)
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje
načítá se...